Geron to Present at Two Key Investor Conferences in May
Event summary
- Geron management to present at Bank of America Securities 2026 Healthcare Conference on May 12 in Las Vegas.
- Virtual presentation scheduled for Stifel Virtual Targeted Oncology Forum on May 20.
- RYTELO® (imetelstat) approved in the U.S. and EU for lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
- Pivotal Phase 3 clinical trial ongoing for imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis.
The big picture
Geron’s upcoming investor presentations come as the company seeks to solidify its position in the blood cancer market following RYTELO’s approvals. The focus on clinical trials and commercialization aligns with broader trends in targeted oncology therapies, where differentiation through novel mechanisms like telomerase inhibition is critical. The company’s ability to articulate its strategic roadmap will be key amid increasing competition in hematologic malignancies.
What we're watching
- Clinical Progress
- The pace at which Geron advances its Phase 3 trial for imetelstat in myelofibrosis will signal pipeline momentum.
- Market Positioning
- Whether Geron can leverage RYTELO’s approvals to expand market share in blood cancer treatments.
- Investor Sentiment
- How conference presentations impact investor confidence amid competitive oncology landscape.